亚宝药业(600351) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 614,533,394.31, representing a decrease of 20.32% compared to CNY 771,213,413.14 in the same period last year[3]. - The net profit attributable to shareholders was CNY 107,269,233.54, down 4.45% from CNY 112,264,323.74 year-on-year[3]. - The net cash flow from operating activities decreased by 48.31%, amounting to CNY 144,398,528.45 compared to CNY 279,357,773.45 in the previous year[3]. - The basic earnings per share were CNY 0.1522, a slight decrease of 0.39% from CNY 0.1528 in the same period last year[3]. - Total operating revenue for Q1 2025 was ¥614,533,394.31, a decrease of 20.3% compared to ¥771,213,413.14 in Q1 2024[18]. - Net profit for Q1 2025 was ¥106,068,467.86, a decrease of 3.1% from ¥109,772,004.55 in Q1 2024[19]. - Basic earnings per share for Q1 2025 were ¥0.1522, slightly down from ¥0.1528 in Q1 2024[20]. - The company reported a decrease in sales expenses to ¥111,914,490.55 in Q1 2025 from ¥200,638,292.84 in Q1 2024, a reduction of 44.2%[18]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,569,135,121.87, reflecting a 0.71% increase from CNY 3,543,942,574.34 at the end of the previous year[4]. - The equity attributable to shareholders increased by 1.72%, reaching CNY 2,942,386,032.98 compared to CNY 2,892,638,654.66 at the end of last year[4]. - As of March 31, 2025, the company's total assets amounted to RMB 3,569,135,121.87, an increase from RMB 3,543,942,574.34 as of December 31, 2024, reflecting a growth of approximately 0.71%[12]. - Total liabilities decreased to ¥625,668,979.44 in Q1 2025 from ¥649,023,044.55 in Q1 2024[15]. Cash Flow - The company's cash and cash equivalents increased to RMB 635,590,969.68 from RMB 578,594,453.98, representing a growth of about 9.3%[12]. - Cash inflow from operating activities in Q1 2025 was ¥556,005,952.75, a decrease of 28.4% compared to ¥776,858,863.98 in Q1 2024[23]. - The net cash flow from operating activities was $144,398,528.45, a decrease of 48.3% compared to $279,357,773.45 in the previous period[24]. - Total cash outflow from operating activities amounted to $411,607,424.30, down from $497,501,090.53, reflecting a reduction of 17.2%[24]. - The ending balance of cash and cash equivalents was $635,254,516.80, compared to $659,775,713.49, reflecting a decrease of 3.7%[25]. - The net increase in cash and cash equivalents was $56,996,515.70, down from $94,311,970.88, representing a decline of 39.4%[25]. Shareholder Information - The company had a total of 49,801 common shareholders at the end of the reporting period[7]. - The largest shareholder, Shandong Yabao Investment Group Co., Ltd., held 94,300,000 shares, accounting for 13.47% of total shares, with 31,150,000 shares pledged[8]. - There were no changes in the top 10 shareholders or their shareholding status compared to the previous period[10]. - The company has not identified any related party transactions or agreements among its major shareholders[10]. Operational Insights - The decline in operating revenue was primarily due to decreased sales from specific products, including the anti-inflammatory patch and injection solutions[6]. - The company reported a significant increase in prepayments, which amounted to RMB 67,669,386.30, slightly down from RMB 71,251,512.37[12]. - The company's non-current assets totaled RMB 1,955,255,613.14, down from RMB 1,984,630,806.62, reflecting a decrease of approximately 1.5%[12]. - The company has not disclosed any new product developments or technological advancements during this reporting period[11]. - Research and development expenses for Q1 2025 were ¥21,567,036.65, down 30.4% from ¥31,012,841.20 in Q1 2024[18].